芬妥木单抗(Figitumumab) - 药物靶点：IGF-1R_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-IGF-1R monoclonal antibody(Pfizer)、Figitumumab (USAN)、CP-751871

靶点

IGF-1R

作用机制

IGF-1R拮抗剂(胰岛素样生长因子-I受体拮抗剂)

治疗领域

肿瘤呼吸系统疾病消化系统疾病+ [6]

在研适应症-

非在研适应症

腺鳞癌晚期乳腺癌晚期癌症+ [20]

原研机构

Pfizer Inc.

在研机构-

非在研机构

Pfizer Inc.

Cliniques Universitaires Saint-Luc

Novartis AG

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 4712393L

来源: *****

Sequence Code 616721995H

来源: *****

关联

37

项与芬妥木单抗相关的临床试验

EUCTR2010-018373-38-GB / Not yet recruitingN/AIIT

A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours - FOREST

开始日期2010-12-17

申办/合作机构

University of Birmingham

ISRCTN12655440 / Completed临床1期IIT

A phase I open label multicentre trial of figitumumab, an insulin-like growth factor 1 receptor (IGFR-1R) antibody, in children aged 1 - 12 years old with relapsed/refractory solid tumour

开始日期2010-08-01

申办/合作机构

University of Birmingham

NCT00907504 / Withdrawn临床3期

Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

Gemcitabine and cisplatin given together is a standard treatment option for advanced lung cancer patients. The purpose of this study is to assess if the life span is longer in patients taking the investigational drug CP-751,871 in combination with gemcitabine and cisplatin compared to gemcitabine and cisplatin alone. Considering a 10% rate of drop-outs, 1,210 participants will be required in order to have an adequate sample size (1,100 evaluable patients) and power to detect a 30% prolongation of survival on the experimental arm.

开始日期2010-07-01

申办/合作机构

Pfizer Inc.

100 项与芬妥木单抗相关的临床结果

登录后查看更多信息

100 项与芬妥木单抗相关的转化医学

登录后查看更多信息

100 项与芬妥木单抗相关的专利（医药）

登录后查看更多信息

81

项与芬妥木单抗相关的文献（医药）

2021-01-01·Advances in experimental medicine and biology4区 · 医学

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer

4区 · 医学

Review

作者: Orafai, Hossein M ; Jamialahmadi, Tannaz ; Mohammadzadeh, Amir Hossein ; Behnam, Behzad ; Sahebkar, Amirhossein ; Panahi, Yunes

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.

2018-05-16·Advances in clinical and experimental medicine : official organ Wroclaw Medical University4区 · 医学

Advances in antibody therapeutics targeting small-cell lung cancer

4区 · 医学

Review

作者: Jiang, Zhiming ; Lu, Hongyang

The proportion of small-cell lung cancer (SCLC) among all lung cancers decreased from 17.26% in 1986 to 12.95% in 2002. Chemotherapy is the key mode of treatment. However, novel therapeutic strategies and drugs are imperative, as the prognosis remains poor. In recent years, antibody therapies have shown promising prospects against malignancy. This review focuses on the advances in antibody therapies in SCLC. Although the results of pembrolizumab, nivolumab, ipilimumab, and rovalpituzumab tesirine are inspiring, all of the clinical trials on these drugs are phase I/II and have been verified for further phase III clinical trials. It was demonstrated that chemotherapy in combination with bevacizumab can improve the progression-free survival (PFS) in phase III trials. The insulin-like growth factor-1 receptor (IGF-1R) is associated with a poor prognosis in SCLC, while the anti-IGF-1R monoclonal antibody figitumumab has a potential therapeutic value. Tarextumab, an antibody that blocks both Notch2 and Notch3 signaling, in combination with etoposide and platinum (EP) in patients with untreated extensive-stage SCLC, proved to be well-tolerated and showed dosedependent anti-tumor activity. The therapeutic effect of sacituzumab govitecan, BW-2 and lorvotuzumab mertansine in SCLC warranted further evaluation. Bec2/BCG as an adjuvant vaccination in patients with limited-disease SCLC could not improve the survival, PFS, or quality of life. Thus, clinical studies are essential to confirm the anti-tumor efficacy of trastuzumab in SCLC.

2018-03-01·Immunotherapy4区 · 医学

Emerging immune targets for the treatment of multiple myeloma

4区 · 医学

Review

作者: Tenneti, Pavan ; Kurtin, Sandra E ; Warraich, Zabih ; Sohail, Atif ; Iftikhar, Ahmad ; Mushtaq, Adeela ; McBride, Ali ; Anwer, Faiz

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

3

项与芬妥木单抗相关的新闻（医药）

2024-06-30

·生物制药小编

肥胖促癌：“3个紊乱”

至少13种肿瘤与肥胖相关（ N Engl J Med 375, 794–798）。 N Engl J Med 375, 794–798 第1乱：胰岛素和雌激素信号紊乱胰岛素受体有两个亚型，IR-A和IR-B，以不同的比例存在于不同的组织中，执行不同的功能。 IR-A在生命早期主要具有促进有丝分裂的作用，它在成年期的表达与胰岛素抵抗和不受调节的细胞增殖有关。IR-B在肝脏和其他成人组织中表达，并主要参与葡萄糖代谢。高水平的IR-A与肿瘤的发生有关，并在多种癌症中被发现，包括乳腺癌、子宫内膜癌、结肠癌和肝细胞癌。与IR-B相比，IR-A对IGF表现出更高的亲和力。IGF-1和IGF-2是在肝脏中响应生长激素而合成的小肽。虽然胰岛素主要以自由形式循环，但IGFs主要与IGF结合蛋白(IGFBPs)结合而循环，从而调节其水平和生物学功能。IGF-1和IGF-2通过与IGF-1受体(IGF-1R)结合，促进细胞生长和增殖，多项研究表明，IGF-1R在乳腺癌和子宫内膜癌中的表达增加。在肥胖的情况下，较高水平的IGF-2同时刺激IGF-1R和IR-A表达。 British Journal of Cancer (2021)125:495–509 肥胖患者，胰岛素和IGFR长期被激活，导致细胞中葡萄糖摄取增加、细胞增殖、血管生成，并最终产生恶性转化和恶性生长的潜力。内脏肥胖（非皮下脂肪肥胖）是比BMI更好的肿瘤风险预测因子。因为内脏肥胖会增加循环的游离脂肪酸，进而增加高胰岛素血症和胰岛素抵抗的发生，增加促炎细胞因子分泌，引起胰岛素受体和IGFR的过度激活，增加PI3K活化，促进肿瘤增殖。临床前模型中，PI3K抑制后，胰岛素的激增可以重新激活这一通路，并刺激进一步的肿瘤细胞增殖。药物靶点：IGF、IR-A、IGF1R、酪氨酸激酶。存在的问题：鉴于IR和IGF1R在人体组织中的普遍存在性，靶向这些受体，会产生off-tumor的相关的毒性。同时阻断IGF1R和IR可导致剂量限制性高血糖，仅抑制IGF1R可导致IR信号通路的代偿性激活。药物举例： IGFR Figitumumab Figitumumab是辉瑞研发的IGF1R单克隆抗体，与卡铂和紫杉醇联合治疗晚期非小细胞肺癌(NSCLC)。然而，由于严重不良事件的发生率增加，包括3/4级高血糖和与治疗相关的死亡，临床试验提前结束。 Linsitinib（OSI-906） Astellas Pharma研发的小分子抑制剂，靶向IGF1R and IR, 3期临床（ NCT00924989）治疗局部晚期或转移性肾上腺皮质癌，和对照组比较，无明显临床获益。没有新的临床研究开展。 IGF2 Dusigitumab/MEDI-573 Dusigitumab由MedImmune LLC研发，IgG2λ抗体，靶向IGF-2 和IGF-1，1期临床（NCT00816361，NCT01340040），最好的结果是疾病稳定（SD），未出现完全缓解（CR）或者部分缓解（PR）。没有新的临床研究开展。 Xentuzumab/BI836845 由Boehringer Ingelheim研发，IgG1抗体，结合IGF-2 和IGF-1，首次人体临床试验（NCT01403974; NCT01317420），显示耐受性良好，125例病人出现2例PR。16例EGFR突变的NSCLC患者（NCT02191891），Afatinib 联合Xentuzumab (BI 836845) Phase1b，没有出现PR，10例SD。NCT02123823，将xentuzumab 加入 everolimus/exemestane，治疗HER2阴性，雌激素受体阳性患者，没有改善PFS，但在没有内脏转移的患者中，观察到了PFS改善，随后开展2期临床XENERA™-1 (NCT03659136)。改变糖稳态重新利用治疗糖尿病的药物在癌症研究领域取得一些进展。二甲双胍在临床前模型中，二甲双胍可下调IGF信号通路，抑制子宫浆液性癌细胞的增殖。二甲双胍还能减弱乳腺癌、肺癌和胰腺癌细胞中IGF1的表达以及mTOR和Akt（胰岛素信号传导的下游效应因子）的激活。在乳腺癌的新辅助治疗中，二甲双胍与其他细胞毒性药物联合使用，改善了病理完全缓解率，但没有改善转移性患者的PFS。用二甲双胍抑制IGF1和PI3K信号通路可以降低子宫内膜肿瘤中的细胞增殖。在small window-of-opportunity（术前）试验中，二甲双胍降低了患者的肿瘤增殖(标记Ki-67)11.75%(P=0.008)，在另一项试验中降低了17.2%(P=0.002)，但这些发现在验证性3期试验中没有得到重复。第2乱：脂肪因子信号通路紊乱脂肪组织分泌的脂肪因子（激素和细胞因子）失调是过度肥胖的一个标志，可以促进肿瘤的生长。瘦素（leptin），脂肪细胞分泌的激素和肥胖的生物标志物，主要功能是下丘脑介导的食欲调节，它调节进食行为和能量消耗。肥胖个体的循环瘦素水平升高，并与癌症发展和进展的风险增加有关，如子宫内膜癌、乳腺癌、结肠癌和肾癌等。瘦素与瘦素受体结合，激活多个信号通路，包括JAK/STAT、MAPK和PI3K通路，最终促进细胞增殖。通过瘦素受体传递的信号也能激活乳腺癌干细胞，是其存活和维持所必需的。胰岛素和IGF1也可以增加乳腺上皮组织中瘦素及其受体的表达，这种表达的增加与乳腺癌预后较差有关。瘦素可以刺激血管生成，增加血管通透性，使恶性细胞进一步生长。因此，瘦素是肿瘤和肿瘤微环境(TME)之间相互作用的重要中介物。 British Journal of Cancer (2021) 125:495–509 另一种由脂肪细胞分泌的激素是脂联素(adiponectin)，它具有抗糖尿病和抗炎的特性。肥胖和代谢综合征血浆脂联素水平降低，脂联素受体(AdipoR1和AdipoR2)的表达也降低，导致脂联素敏感性进一步降低。低脂联素水平与胰岛素抵抗和肥胖相关恶性肿瘤的风险增加有关，包括乳腺癌和子宫内膜癌。脂联素激活AMPK通路，导致p53和p21的上调，从而调控细胞周期和凋亡。肥胖增加瘦素，降低脂联素水平，瘦素/脂联素比值被认为是乳腺癌生长的一个预测因子。其他脂肪因子的水平，如抵抗素（resistin）和内脂肪素（visfatin），在肥胖人体升高，是炎症的标志物，与各种癌症的发展和进展有关。抵抗素（resistin）被认为通过TLR4介导NF-κB和STAT3的激活来促进乳腺癌细胞的生长。药物靶点瘦素虽然瘦素和肿瘤发生发展的关系已经确定，但是目前尚无拮抗瘦素的药物进入临床。PEG-LPrA2是一种瘦素受体拮抗剂，已在三阴性乳腺癌的临床前模型中被研究，可以抑制瘦素信号通路并抑制乳腺癌的生长。脂联素 PPAR合成配体（罗格列酮和吡格列酮），是糖尿病治疗药物，通过调节葡萄糖代谢、减少高胰岛素血症和改变脂肪酸代谢。此外，PPARγ合成配体已被证明在临床前模型和人体研究，显示增加脂联素水平，可能有利于治疗肥胖驱动的癌症。 Statins 他汀类药物被广泛用于脂质水平管理，也可能具有抗癌特性。已经提出了几种抗癌机制的作用：通过抑制Ras和Rho激活，损害肿瘤细胞增殖；通过细胞周期阻滞抑制细胞增殖；诱导凋亡；剂量依赖性抑制血管生成；适当抗炎。但是临床结果并不一致。第3乱：雌激素信号紊乱 British Journal of Cancer (2021)125:495–509 绝经后，雌激素主要来自于雄激素转化（通过雌激素生物合成酶，芳香化酶）。肥胖引起癌症发生的一个重要因素就是增加脂肪组织中芳香化酶活性。芳香化酶抑制剂二甲双胍已被确定为一种潜在的乳腺特异性芳香化酶抑制剂。脂肪因子adiponectin和ghrelin也被证明以启动子特异性的方式抑制芳香化酶的表达，这可能有助于解释肥胖环境下低水平脂联素与乳腺癌生长之间的联系。特异性甾体和非甾体芳香化酶抑制剂已证明对预防和治疗ER+乳腺癌有效，ER+乳腺癌发展或复发的风险降低约50%。芳香化酶抑制剂也可能在ER+子宫内膜癌中有临床应用，但目前临床疗效有限。 Anastrozole是一种非甾体芳香化酶抑制剂，已被证明在新辅助治疗中可减少子宫内膜癌细胞的增殖，并对治疗复发性ER+子宫内膜癌具有一定的活性。 Trozole（非甾体芳香化酶抑制剂）联合everolimus（mTOR抑制剂），未被选择的子宫内膜癌人群中，总有效率为32%。 Exemestane一种不可逆的甾体芳香化酶抑制剂，目前正在被测试用于治疗子宫内膜增生和低级别子宫内膜癌(NCT03300557)。其他正在进行的试验，正在评估芳香化酶抑制剂与PI3K-mTOR通路抑制剂的各种组合(NCT02730923，NCT03008408)。饮食控制及体育锻炼饮食控制和体育锻炼，可以显著改善机体的炎症因子水平，恢复机体代谢稳态。国内和国际上，都有一些临床试验在评估其价值。主要参考文献 Lauby-Secretan B, Scoccianti C, Loomis D,Grosse Y, Bianchini F & Straif K (2016) Body fatness and cancer – viewpointof the IARC Working Group. N Engl J Med 375, 794–798 Johann de Bono et al, Two first-in-humanstudies of xentuzumab, a humanised insulin-like growth factor(IGF)-neutralising antibody,in patients with advance）dsolid tumours，British Journal of Cancer https://doi-org.libproxy1.nus.edu.sg/10.1038/s41416-020-0774-1 Goodwin, P., Ennis, M., Cescon, D., Elser,C., Haq, R., Hamm, C. et al. Abstract P1- 16-03: phase II randomized clinicaltrial (RCT) of metformin (MET) vs placebo (PLAC) in combination withchemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breastcancer (MBC). Cancer Res. 79, P1-16-03–P11-16-03 (2019) Maria M. Rubinstein, Kristy A. Brown andNeil . Iyengar. Targeting obesity-related dysfunction in hormonally drivencancers. British Journal of Cancer (2021) 125:495–50

临床结果临床2期

2023-12-14

·Business Wire

Insulin-Like Growth Factor Immunotherapy Advances: Crucial Findings on IGF-1R-Inhibiting Therapies Unveiled in Latest Research Publication - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This research explores the current landscape of immunotherapy treatments targeting the insulin-like growth factor-1 receptor (IGF-1R), a significant player in oncological advancements. The detailed study delves into the intricate relationships between IGF-1R and various cancer types, offering valuable insights into the prospects and challenges of IGF-1R inhibitors and associated therapeutic approaches. IGF-1R Immunotherapy's Role Beyond Oncology The research publication also captures the significance of IGF-1R inhibition in conditions beyond cancer, particularly noting its overexpression in immune cells related to thyroid ophthalmopathy in Graves' disease. Understanding the role of IGF-1R can lead to enhanced therapeutic interventions aimed at mitigating inflammatory processes and improving symptoms in affected patients. This robust body of work encapsulates the critical developments in IGF-1R-targeted immunotherapy, offering a treasure trove of information to stakeholders in the biopharmaceutical industry, research institutions, healthcare professionals, and policy-makers. Expanding IGF-1R Inhibition Therapeutics: A Glimpse into the Future The document underscores the complexities and potential of targeting IGF-1 receptor pathways, thrusting readers to the forefront of immunotherapeutic innovation. The nuanced findings in our report are crucial for guiding future research directions, optimizing treatment regimens, and ultimately enhancing patient care within the realm of precision medicine. The discoveries and analyses presented in this publication not only illuminate the path for future scientific inquiries but also underpin the strategic decisions that will shape the next generation of IGF-1R-targeted therapies. The implications of the findings extend to translational research, clinical application, and the broader biotech industry's approach to disease treatment and patient well-being. For those committed to staying abreast of the latest breakthroughs in targeted immunotherapy, exploring the wealth of information housed within the pages of this research document is indispensable. Key Highlights and Innovations in IGF-1R Immunotherapy The document presents critical developments through a tabulated competitors' overview, covering essential details such as drug codes, targets or mechanisms of action, compound classes, territorial reach of key competitors, indications, and the current stages of research and development. An in-depth project history section, providing links to relevant sources of information, including press releases, company homepages, academic abstracts, presentations, and annual reports, further enriches the report's content. Insightful analysis of past and ongoing clinical trials, including the performance of monoclonal antibodies such as figitumumab, ganitumab, and dalotuzumab in various phases of testing, with special emphasis on phase III clinical outcomes. Exploration of cutting-edge strategies that leverage IGF-1R's cell-signaling dynamics for targeted drug delivery, such as the use of antibody-drug conjugates and radioimmunoconjugates. For more information about this report visit https://www.researchandmarkets.com/r/litbge About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

免疫疗法AACR会议ASCO会议

2023-08-15

·PipelineReview

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

BARCELONA, Spain I August 15, 2023 I La Merie Publishing released its newest product reviewing the pipeline of IGF-1R or IGF-1 targeted drugs or immunotherapy candidates: IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review Target: Insulin-like growth factor-1 (IGF-1) & Receptor (IGF-1R Product Category: Antibody; Fusion Protein This product provides basic information on approved drugs and immunotherapy candidates in research and development targeting insulin-like growth factor-1 (IGF-1) or its receptor (IGF-1R). This product consists of: This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day. IGF-1R is a key member of the insulin-like growth factor (IGF) axis, which involves in cancer development, metastasis and cancer therapeutic resistance. Anti-IGF-1R monoclonal antibody is among the first major therapeutic agents for IGF-1R inhibition. These antibodies inhibit the binding between IGF-1R and its ligands, thereby blocking the activation of IGF-1R homodimer and IGF-1R/InsR hybrid, but not the InsR homodimer. A number of fully human monoclonal antibodies, which target the α subunit of IGF-1R, have demonstrated anti-tumor activities in pre-clinical studies. After completion of early phase clinical trials, three of the IGF-1R antibodies (figitumumab, ganitumab, and dalotuzumab) were tested in phase III clinical trials. Another strategy is inhibiting the binding of IGF ligands to the receptor which can inactivate IGF-1R. Due to the lack of a clear clinical benefit in these phase III trials, further clinical research was not pursued. Meanwhile, several firms are taking advantage of elevated IGF-1 signaling in cancers to deliver therapeutic payloads directly to tumor tissue, e.g. by antibody-drug conjugates or radioimmunoconjugates. These drug programs exploit the fact that IGF-1R, upon binding to its ligand or an antibody, undergoes receptor-mediated endocytosis, resulting in internalization of any bound molecules. Off-target toxicity is minimized because IGF-1R activity is mostly limited to internal compartments of the cell in vital organs such as the heart, and only a few tissues in the bladder, prostate and endometrium show low to moderate surface expression of IGF-1R. IGF-1R is a transmembrane tyrosine kinase receptor that plays a role in development, metabolism, and immune regulation, and is overexpressed in orbital fibroblasts (OFs), B, and T cells of thyroid ophthalmopathy in Graves' disease. Blocking IGF-1(R) signalling reduces the expression of downstream inflammatory factors, thereby inhibiting the synthesis of hyaluronic acid and other glycosaminoglycan caused by OFs activation, as well as related inflammatory reactions including tissue congestion and edema; inhibit adipocyte cellularization of OFs, thereby reducing the disease activity of patients with active thyroid ophthalmopathy and improving proptosis, diplopia, ocular congestion and edema and other symptoms and signs. The report “ IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review ” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/igf-1r-and-igf-1-targeted-immunotherapy-pipeline-review/ About La Merie Publishing La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers. La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest. SOURCE: La Merie Publishing

免疫疗法临床3期临床结果

100 项与芬妥木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09345	芬妥木单抗	-	DB11685

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床3期	美国	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	比利时	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	巴西	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	保加利亚	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	加拿大	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	智利	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	捷克	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	法国	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	希腊	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	匈牙利	Pfizer Inc.	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00372996 (CTgov)	临床2期	HR阳性乳腺癌	219	CP-751,871+Exemestane (CP-751,871 + Exemestane)	壓窪遞衊遞觸觸選繭夢(艱糧遞齋鹽壓廠願選襯) = 糧鹹製繭繭顧醖遞膚築觸憲範糧醖夢範夢壓遞 (壓選壓鬱蓋網鏇糧築遞, 鑰壓鹽願蓋廠憲醖築構 ~ 衊醖鏇壓鬱艱鏇壓襯獵) 更多	-	2015-07-28
				Exemestane (Exemestane)	壓窪遞衊遞觸觸選繭夢(艱糧遞齋鹽壓廠願選襯) = 齋蓋夢鏇廠餘遞衊選淵觸憲範糧醖夢範夢壓遞 (壓選壓鬱蓋網鏇糧築遞, 鹽膚顧廠繭網艱鏇鏇蓋 ~ 壓願觸鬱獵網鹽壓積觸) 更多
NCT00673049 (Pubmed \| Ann Oncol) 人工标引	临床3期	非小细胞肺癌二线	583	erlotinib+figitumumab	鹹膚獵窪淵鹽壓願網觸(鏇淵廠鏇選齋醖艱夢艱) = 壓製觸簾網鏇齋鑰廠夢膚蓋廠壓鹽簾醖淵廠鑰 (鑰選廠憲廠廠鏇鑰鏇淵 ) 更多	不佳	2015-03-01
				erlotinib	鹹膚獵窪淵鹽壓願網觸(鏇淵廠鏇選齋醖艱夢艱) = 齋糧獵鹹獵蓋構觸遞願膚蓋廠壓鹽簾醖淵廠鑰 (鑰選廠憲廠廠鏇鑰鏇淵 ) 更多
NCT00596830 (Pubmed \| J Urol)	临床3期	晚期非小细胞肺癌一线	681	Figitumumab plus paclitaxel and carboplatin	簾獵鹹遞範醖襯壓窪淵(顧餘窪簾窪構醖蓋壓繭) = 衊築獵淵鬱積獵廠憲鑰觸繭衊築網膚餘襯鑰齋 (窪顧壓鬱鑰夢簾鏇遞餘 ) 更多	不佳	2014-07-01
				Paclitaxel and carboplatin alone	簾獵鹹遞範醖襯壓窪淵(顧餘窪簾窪構醖蓋壓繭) = 鹽鹽廠膚膚範糧選製製觸繭衊築網膚餘襯鑰齋 (窪顧壓鬱鑰夢簾鏇遞餘 ) 更多
NCT00729833 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	45	Figitumumab+Sunitinib (Figitumumab 10 mg/kg + Sunitinib 25 mg CDD)	鬱築遞窪簾鏇範襯構淵(鏇衊顧襯顧鑰襯觸獵築) = 遞鹽獵網襯構壓觸觸壓願壓選鏇鏇窪範繭襯願 (膚糧築積範築蓋遞製廠, 壓鏇簾鏇糧製衊醖鹽繭 ~ 鹹廠鑰鑰製顧積構憲糧) 更多	-	2014-06-09
				Figitumumab+Sunitinib (Figitumumab 10 mg/kg + Sunitinib 37.5 mg CDD)	鬱築遞窪簾鏇範襯構淵(鏇衊顧襯顧鑰襯觸獵築) = 獵簾獵淵簾觸鹹顧夢餘願壓選鏇鏇窪範繭襯願 (膚糧築積範築蓋遞製廠, 繭構鑰鑰淵餘願願構壓 ~ 糧願夢選淵顧襯憲醖蓋) 更多
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	艱壓顧餘鑰餘夢顧鏇獵(選窪鑰廠齋鬱願製鹹鑰) = 醖壓繭艱鏇獵艱鏇網糧簾鑰齋淵積艱選簾鏇膚 (顧齋夢觸艱廠窪構衊襯, 艱積壓鑰艱製鹽艱鹹鬱 ~ 遞鏇淵遞齋鹽遞鏇廠餘) 更多	-	2013-12-13
				Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	艱壓顧餘鑰餘夢顧鏇獵(選窪鑰廠齋鬱願製鹹鑰) = 窪願繭選鹽遞顧簾觸製簾鑰齋淵積艱選簾鏇膚 (顧齋夢觸艱廠窪構衊襯, 繭鬱襯壓鹽範壓鬱鬱網 ~ 鏇夢願選顧鬱蓋淵願觸) 更多
NCT00596830 (CTgov)	临床3期	腺鳞癌 \| 大细胞癌 \| 非小细胞肺癌 ... 更多	681	Figitumumab+Carboplatin+Paclitaxel (Figitumumab + Paclitaxel and Carboplatin)	鹽醖襯鬱醖壓選遞淵襯(壓鬱網醖廠膚齋鹹鑰築) = 夢淵獵醖夢遞鏇醖餘窪構顧糧簾鹽醖築簾製選 (觸願鹽廠網憲膚遞壓蓋, 獵築簾艱繭積遞製遞鹽 ~ 鏇蓋鬱積蓋繭範膚繭築) 更多	-	2013-12-03
				Carboplatin+Paclitaxel (Paclitaxel and Carboplatin (Chemo))	鹽醖襯鬱醖壓選遞淵襯(壓鬱網醖廠膚齋鹹鑰築) = 製範顧網鏇顧憲鑰繭範構顧糧簾鹽醖築簾製選 (觸願鹽廠網憲膚遞壓蓋, 窪構鏇蓋艱遞憲簾網簾 ~ 膚窪鬱夢餘鹹艱餘餘齋) 更多
NCT01653158 (CTgov)	临床1期	晚期恶性实体瘤	46	CP-751,871+Docetaxel (CP-751,871 0.1-20 mg/kg + Docetaxel)	製齋簾餘憲簾觸窪顧觸(艱積築憲獵齋遞衊鏇醖) = 鑰齋夢築糧遞艱築製鏇廠鑰鏇襯醖鑰壓齋願膚 (顧餘製選鹹觸顧觸窪鏇, 構廠窪齋糧遞鹽選鑰積 ~ 衊構廠衊積壓遞醖簾襯) 更多	-	2013-08-27
				CP-751,871+Docetaxel (CP-751,871 20 mg/kg + Docetaxel)	鬱齋衊簾鬱遞範願構製(憲夢築鹽範憲夢壓齋窪) = 鹹襯膚鏇繭艱積鏇簾願憲網艱窪觸衊醖醖淵觸 (鬱醖選範構鹹網廠築襯, 襯獵積蓋網膚鑰築網觸 ~ 鏇糧蓋齋繭壓鬱願觸醖) 更多
NCT00673049 (CTgov)	临床3期	腺鳞癌 \| 大细胞癌 \| 晚期非小细胞肺癌 ... 更多	583	Figitumumab+Erlotinib (Figitumumab + Erlotinib)	齋遞醖遞齋淵築艱積遞(網醖觸鹹膚選醖築蓋製) = 膚積夢衊餘膚遞鏇願壓醖餘憲範衊鏇獵蓋憲夢 (築遞築築艱膚網繭鏇鹽, 築鏇鹽鏇築鹽築繭範鏇 ~ 鹽築膚繭製夢齋壓遞鬱) 更多	-	2013-07-24
				Erlotinib (Erlotinib)	齋遞醖遞齋淵築艱積遞(網醖觸鹹膚選醖築蓋製) = 網遞鹹網鬱餘網膚鹹鬱醖餘憲範衊鏇獵蓋憲夢 (築遞築築艱膚網繭鏇鹽, 顧齋選獵夢獵衊顧齋鬱 ~ 構鬱餘顧獵網選觸築襯) 更多
NCT00560560 (CTgov)	临床2期	结直肠癌	168	Figitumumab (Figitumumab 20 mg/kg)	醖齋鏇遞鏇獵齋製鏇齋(鏇鏇製膚顧齋鬱獵鬱壓) = 網憲艱範繭淵製鹹艱遞襯觸艱鬱積繭簾醖鏇餘 (顧製鏇顧齋艱糧鬱衊觸, 觸壓醖壓鹹製壓獵積廠 ~ 艱廠廠鬱憲顧餘選夢選) 更多	-	2013-05-09
				Figitumumab (Figitumumab 30 mg/kg)	醖齋鏇遞鏇獵齋製鏇齋(鏇鏇製膚顧齋鬱獵鬱壓) = 鑰餘簾範膚糧積築蓋淵襯觸艱鬱積繭簾醖鏇餘 (顧製鏇顧齋艱糧鬱衊觸, 選顧鬱醖鹹鹽積願窪鬱 ~ 鏇糧鹽壓艱鏇淵衊餘網) 更多
NCT00313781 (CTgov)	临床2期	去势抵抗性前列腺癌	204	CP-751,871+Prednisone+Docetaxel (CP-751,871+Docetaxel+Prednisone)	醖築蓋膚鏇築簾範齋蓋(鹹餘蓋齋構鹽夢餘醖齋) = 網襯積選鹽製糧窪築鹽網鏇顧糧鏇獵醖製膚簾 (觸艱範壓網鬱製繭繭範, 窪鏇鹹顧衊網夢遞簾蓋 ~ 願顧鏇糧壓餘範範餘襯) 更多	-	2013-04-11
				Prednisone+Docetaxel (Docetaxel+Prednisone)	醖築蓋膚鏇築簾範齋蓋(鹹餘蓋齋構鹽夢餘醖齋) = 膚艱構齋範鬱糧襯夢遞網鏇顧糧鏇獵醖製膚簾 (觸艱範壓網鬱製繭繭範, 夢齋選製膚齋鹹鹽積範 ~ 繭艱齋鬱鹹鑰艱積淵廠) 更多